Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q

NCT03223961 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT03223961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03223961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 26, 2018
Completion date
October 1, 2028
Enrollment
124 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes